Select Your Region
Global
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- Breast Cancer
Trial Status:
Active, not recruiting
This trial runs in
Cities
- Barranquilla
- Bogotá
- Buenos Aires
- Cali
- Ceará
- Cercado de Lima
- Ciudad de Guatemala
- Ciudad de México
- Córdoba
- Floridablanca
- HPR
- KZE
- La Habana
- Las Condes
- Montevideo
- Paraná
- Rio de Janeiro
- Rio Grande do Sul
- Rosario
- San Isidro
- San Pedro Garza García
- Santiago
- Santo Domingo
- Surquillo
- São Paulo
- Temuco
- Toluca de Lerdo
Trial Identifier:
NCT04158258 MO39485
Trial Summary
A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.
Hoffmann-La Roche
Sponsor
NCT04158258 , MO39485
Trial Identifier
Bevacizumab, Trastuzumab, Ado-trastuzumab emtamsine, Pertuzumab, Atezolizumab, Capecitabine
Treatments
Breast Cancer
Condition
Official Title
A STUDY TO OBSERVE PATIENTS CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED BREAST CANCER IN LATIN AMERICA
Eligibility Criteria
All
Gender
≥18 Years
Age
Inclusion Criteria
- Histological confirmed newly diagnosed stage I to IV (recurrent or de novo) breast cancer no more than 12 months prior to site activation, although they can have received anti-cancer treatment during that time
Exclusion Criteria
- Patients not receiving treatment for breast cancer with national approved drugs according to standard of care and in line with the current summary of product characteristics (SPC) /local labeling
- Patients not receiving the Roche studied medicinal product, but a biosimilar
For the latest version of this information please go to www.forpatients.roche.com